Abstract | OBJECTIVE: CASE SUMMARIES: The first case concerns a 60-year-old man who reported tinnitus when he reached a 180 mg/d dose of baclofen after 3 months of treatment. Tinnitus persisted until the dose was reduced to 90 mg/d. The second case concerns a 45-year-old woman who presented with tinnitus when she reached a 210 mg/d dose of baclofen after 4 months of treatment. Tinnitus persisted until the dose was reduced to 60 mg/d. DISCUSSION: Using the Naranjo scale, imputability to baclofen was considered probable in both cases. GABA-B receptors have been reported to be implicated in both the etiology and the treatment of tinnitus. There may be an individual susceptibility to develop tinnitus under baclofen therapy because of some GABA-B genetic polymorphisms that remain to be determined. CONCLUSION: HDB may be responsible for the occurrence of severe tinnitus, possibly in a dose-dependent manner. This appears to be coherent with the previously known involvement of GABA-B receptors in the pathophysiology of tinnitus.
|
Authors | Marine Auffret, Benjamin Rolland, Sylvie Deheul, Vincent Loche, Catherine Hennaux, Olivier Cottencin, Régis Bordet, Sophie Gautier, CAMTEA Team |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 48
Issue 5
Pg. 656-9
(May 2014)
ISSN: 1542-6270 [Electronic] United States |
PMID | 24577148
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- GABA-B Receptor Agonists
- Muscle Relaxants, Central
- Baclofen
|
Topics |
- Alcoholism
(drug therapy)
- Baclofen
(adverse effects)
- Dose-Response Relationship, Drug
- Female
- GABA-B Receptor Agonists
(adverse effects)
- Humans
- Male
- Middle Aged
- Muscle Relaxants, Central
(adverse effects)
- Off-Label Use
- Tinnitus
(chemically induced)
|